Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViroGates ASFRA:EP2 24 Cash Ratio is 3.20 as of Mar. 2026, which is 48% below its 10-year median of 6.13. GuruFocus rates FRA:EP2 with a GF Score™ of 24/100 and a GF Value™ of €0.87 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 837 Medical Devices & Instruments companies, ViroGates AS ranks better than 78.97% on this metric.
ViroGates AS has a Cash Ratio of 3.20. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for ViroGates AS's Cash Ratio or its related term are showing as below:
FRA:EP2'
s Cash Ratio Range Over the Past 10 Years
Min: 0.74 Med: 6.13 Max: 24.91
Current: 3.2
During the past 10 years, ViroGates AS's highest Cash Ratio was 24.91. The lowest was 0.74. And the median was 6.13.
FRA:EP2's Cash Ratio is ranked better than 78.97% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs FRA:EP2: 3.20
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
ViroGates AS Cash Ratio Related Terms
ViroGates AS Cash Ratio Historical Data
* Premium members only.
The historical data trend for ViroGates AS's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ViroGates AS's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Cash Ratio distribution charts can be found below:
* The bar in red indicates where ViroGates AS's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS (FRA:EP2) has a Cash Ratio of 3.20 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ViroGates AS and its competitors. This is 48% below median its historical median of 6.13. Over the past decade, ViroGates AS's Cash Ratio has ranged from 0.74 to 24.91. According to the industry distribution chart, ViroGates AS ranks #176 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is ViroGates AS's Cash Ratio too high?
ViroGates AS's current Cash Ratio of 3.20 is 48% below median its 10-year median of 6.13. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 24.91. The Medical Devices & Instruments industry median Cash Ratio is 0.95. ViroGates AS's value of 3.20 is 236.8% above this industry median. Based on the distribution chart, ViroGates AS ranks #176 out of 837 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ViroGates AS has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #176 out of 837 companies for Cash Ratio. This places ViroGates AS in the top 21% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.95. ViroGates AS's value of 3.20 is 236.8% above this benchmark. Historically, ViroGates AS's own Cash Ratio has ranged from 0.74 to 24.91 over the past decade. While the company's 10-year median is 6.13 vs. the industry median of 0.95, ViroGates AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.95, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ViroGates AS's current Cash Ratio of 3.20 is 236.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current Cash Ratio is 3.20, which is 48% below median its own 10-year median of 6.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (FRA:EP2) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.87, compared to a current price of €1.45 — trading 66.7% above its estimated fair value. The current Cash Ratio is 3.20, which is 48% below median its 10-year median of 6.13 and 236.8% above the Medical Devices & Instruments industry median of 0.95. ViroGates AS's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current Cash Ratio is 3.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (FRA:EP2) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of €1.45 is trading 66.7% above its estimated GF Value™ of €0.87.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for FRA:EP2:
Cash Ratio: 3.20 (48% below median its 10-year median of 6.13)
GF Value™: €0.87 vs. price of €1.45 (66.7% above fair value)
Industry Position: 236.8% above the Medical Devices & Instruments median (#176 of 837)
No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
24GF Score
Get the complete analysis for FRA:EP2
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EP2 has been successfully added to your 
